Expert Commentary: Practice-Changing Advances in Type 2 Diabetes

Learn expert perspectives on pivotal studies of SGLT2 inhibitors in type 2 diabetes including possible renal protection in those with or without established chronic kidney disease.

Share

Program Content

Activities

Renal Protection in T2D
Why I Recommend SGLT2 Inhibitors for Renal Protection in Patients With T2D
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: June 21, 2021

Expires: June 20, 2022

Faculty

cover img faculity

Richard E. Pratley, MD

Samuel E. Crockett Chair in Diabetes Research
Medical Director
AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins University School of Medicine 
Orlando, Florida

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Merck